POSIFLEX-TECHNOLOGY
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, is pleased to announce that its Haydn ZT Series - the industry's first clamshell POS terminal with a patented modular design and exceptional serviceability - and its Gen9 Base, which integrates a thermal printer and power supply for maximum space efficiency, have been awarded the iF DESIGN AWARD 2024 in the discipline of Product in the Public/Retail category by the Hannover-based iF International Forum Design GmbH, which is one of the most coveted accolades in the world of design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314845350/en/
Posiflex Wins the iF DESIGN AWARD 2024 for Haydn ZT Series and Gen9 Base (Graphic: Business Wire)
The Posiflex Haydn ZT Series and Gen9 Base stood out from a field of nearly 11,000 entries from 72 countries, impressing the 132-strong jury of independent experts from around the world with innovative designs and technical excellence aimed at delivering the highest levels of convenience and value to users and consumers.
Haydn ZT Series: The Industry's First Clamshell POS Terminal
The Posiflex Haydn ZT Series redefines the mechanical structure of POS terminals with the world's first clamshell design. This design simplifies maintenance tasks by allowing the monitor to be effortlessly lifted with just a slide of the hidden lever. It provides convenient access to internal modular components and facilitates easy and seamless repairs, replacements, and upgrades. Such innovation promises to significantly reduce downtime in case of a crash, minimizing inconvenience and financial losses associated with such incidents.
Gen9 Base: A Multi-Functional POS Terminal Base
The Gen9 Base is a multi-functional POS terminal base that integrates a built-in high-speed 250mm/second thermal receipt printer with auto-cutter concealed within its lightweight, screwless housing, in addition to hidden I/O, power and cabling designs, all of which combine to achieve a clean and stylish look and a clutter-free countertop. The POS terminal base also offers the option of a second monitor, expandable up to 15.6 inches, for maximum space efficiency and convenience for users and consumers.
Owen Chen, CEO of Posiflex Technology remarked, "Winning the iF DESIGN AWARD 2024 for our Haydn ZT Series and Gen9 Base is a testament to Posiflex's relentless pursuit of excellence in product design and innovation. Posiflex has been committed to pushing the boundaries of technological innovation to enhance the experiences of our customers worldwide.”
Being recognized by the esteemed iF International Forum Design GmbH reaffirms our position as a leader in the industry and motivates us to continue delivering cutting-edge solutions that meet the evolving needs of our customers. The Haydn ZT POS terminal series and Gen9 Base epitomize our dedication to innovation-driven entrepreneurship and unwavering focus on putting our customers first.
More information about The Haydn ZT Series and Gen9 Base can be found at: https://ifdesign.com/en/search?find=posiflex
About POSIFLEX Group
Posiflex Group is a leading global Commercial Internet of Things (CIoT) platform powered by smart Online-to-Offline (O2O) and Software-agnostic Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314845350/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom